In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dexcom Inc.

www.dexcom.com

Latest From Dexcom Inc.

Medtronic And Novo Nordisk To Collaborate On Diabetes Devices

The companies signed a deal to allow Novo Nordisk’s smart insulin pens to share insulin dosing data with Medtronic’s continuous glucose monitoring devices. Novo Nordisk's smart insulin pens are already compatible with all other major brands of continuous glucose monitors.

Commercial Deals

Exec Chat: ResMed's CEO Mick Farrell Outlines 2025 Strategy For 250 Million Users

ResMed's CEO Mick Farrell outlined the company's 2025 strategy: double-digit growth, drive up its user base to 250 million people and becoming the leading digital health company in both sleep apnea and chronic obstructive pulmonary (COPD) disease. Medtech Insight sat down with Farrell at ResMed's San Diego headquarters to learn more.

Exec Chat Digital Health

Market Intel: CGM Market Competition And Device Interoperability Were Hot Topics At ADA2019

Interoperability and the rising use of continuous glucose monitoring is fueling competition among diabetes device-makers and dominated the conversation at the recent annual ADA meeting.

Market Intelligence Diabetic Care

Dexcom Stocks Continue To Drop After Short-Seller Warns of Competition From Abbott

Investment managing firm Spruce Point says factors such as patients hacking their older Dexcom continuous glucose meters, the company’s decision to not disclose its patient base and competition from Abbott’s upcoming Libre 2 CGMs are red flags that Dexcom is overstating its market potential. Dexcom's stocks lost a fifth of their value after the short-seller released a recent report that says the firm is overvalued.

Market Access Pricing Strategies
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Biosensors
    • Glucose Testing
  • Medical Devices
    • Monitoring Equipment & Devices
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Dexcom Inc.
  • Senior Management
  • Kevin Sayer, Pres. & CEO
    Quentin Blackford, CFO & COO
    Richard B Doubleday, Chief Commercial Officer
    Jacob Leach, CTO
    Steven Pacelli, EVP, Strategy & Corp. Dev.
  • Contact Info
  • Dexcom Inc.
    Phone: (858) 200-0200
    6340 Sequence Dr.
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register